Cargando…

Anti-platelet drugs and their necessary interaction with endothelial mediators and platelet cyclic nucleotides for therapeutic efficacy()

For many millions of patients at secondary risk of coronary thrombosis pharmaceutical protection is supplied by dual anti-platelet therapy. Despite substantial therapeutic developments over the last decade recurrent thrombotic events occur, highlighting the need for further optimisation of therapies...

Descripción completa

Detalles Bibliográficos
Autores principales: Knowles, Rebecca B., Warner, Timothy D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Pergamon Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325790/
https://www.ncbi.nlm.nih.gov/pubmed/30081048
http://dx.doi.org/10.1016/j.pharmthera.2018.08.004